Trial Purpose

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.

Learn More on ClinicalTrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT03407144

When speaking to your doctor, please have the trial identifier number available.

About The Study

Patients that have an inadequate response to chemotherapy will receive study medication (pembrolizumab) in addition to continuing chemotherapy. Radiotherapy may or may not be an option.

Patients that have an adequate response to chemotherapy will not receive any further study treatment. Your study doctor will determine your next treatment per standard of care and will discuss this with you in more detail.

Trial Phase Icon

Phase 2

Tests the medicine or vaccine in approximately 100 to 500 volunteers. In the case of medicines, volunteers usually have the disease or condition the investigational medicine is designed to treat. In vaccine studies, the volunteers are usually healthy.

Trial start Icon

Dates

  • Actual study start date 9 April 2018
  • Estimated primary completion date 13 February 2027
  • Estimated study completion date 13 February 2027

Eligibility

Only a qualified healthcare professional can determine your eligibility. However, this information may be useful in starting a conversation with your doctor.

Conditions Icon

Conditions

Hodgkin Lymphoma

Age Range Icon

Age Range

3 - 25

Sex Icon

Sex

All

Trial locations

Locations provided may not reflect the most current site information. Please call the number provided in the location results to confirm.